Ramakrishna Nirogi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3374828/publications.pdf

Version: 2024-02-01

75	795	471509	580821
papers	citations	17 h-index	25 g-index

85	85	85	1109
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Short-term toxicity study of 1-aminobenzotraizole, a CYP inhibitor, in Wistar rats. Drug and Chemical Toxicology, 2022, 45, 1597-1605.	2.3	2
2	1â€[2â€(1â€Cyclobutylpiperidinâ€4â€yloxy)â€6,7â€dihydroâ€4Hâ€thiazolo[5,4â€c]pyridinâ€5â€yl]propanâ€1â€one: a Histamine H₃ Receptor Inverse Agonist with Efficacy in Animal Models of Cognition. ChemMedChem, 2022, 17, .	3.2	3
3	A selective and accurate liquid chromatography-tandem mass spectrometry method for the quantitation of the novel 5-HT4 receptor partial agonist SUVN-D4010 (Usmarapride) in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2022, 211, 114617.	2.8	1
4	Ropanicant (SUVN-911), an Î±4Î²2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization. Psychopharmacology, 2022, 239, 2215-2232.	3.1	4
5	Effect of masupirdine (SUVNâ€502) on cognition in patients with moderate Alzheimer's disease: A randomized, doubleâ€blind, phase 2, proofâ€ofâ€concept study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	6
6	Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders. Journal of Psychopharmacology, 2021, 35, 713-729.	4.0	4
7	Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology, 2021, 238, 1495-1511.	3.1	8
8	First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects. Clinical Drug Investigation, 2021, 41, 469-482.	2.2	4
9	Evaluation of monoamine oxidase A and B type enzyme occupancy using non-radiolabelled tracers in rat brain. Neurochemistry International, 2021, 145, 105006.	3.8	1
10	Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT₄ Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2021, 64, 10641-10665.	6.4	8
11	Masupirdine (SUVNâ€502): A promising clinical candidate for the management of agitation in Alzheimerâ€™s dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
12	Masupirdine in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Subgroup analyses of memantine regimen, plasma concentrations and duration of treatment. Alzheimer's and Dementia, 2020, 16, e039254.	0.8	1
13	Masupirdine (SUVNâ€502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patientâ€™s age on efficacy endpoints. Alzheimer's and Dementia, 2020, 16, e039283.	0.8	0
14	Masupirdine (SUVNâ€502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039303.	0.8	3
15	LCâ€“MS/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment. Bioanalysis, 2020, 12, 533-544.	1.5	1
16	Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. Clinical Drug Investigation, 2020, 40, 603-615.	2.2	5
17	The use of inactivated brain homogenate to determine the inÂvitro fraction unbound in brain for unstable compounds. Xenobiotica, 2020, 50, 1228-1235.	1.1	1
18	Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy. European Journal of Pharmaceutical Sciences, 2020, 152, 105425.	4.0	5

#	Article	IF	Citations
19	Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine Î±4Î²2 Receptor Antagonist for the Treatment of Depression. Journal of Medicinal Chemistry, 2020, 63, 2833-2853.	6.4	18
20	SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization. Behavioural Pharmacology, 2019, 30, 16-35.	1.7	26
21	Determination of Clastogenic and Anticlastogenic Potential of Cuminum Cyminum Seed Oil Using in Vitro Micronucleus Assay in CHO-K1 Cells. Journal of Herbs, Spices and Medicinal Plants, 2019, 25, 259-270.	1.1	1
22	LCâ€“MS/MS method for quantification of 3,4-dihydroxyphenylglycol, a norepinephrine metabolite in plasma and brain regions. Bioanalysis, 2019, 11, 971-986.	1.5	1
23	0120 SUVN-G3031, a Novel, Potent and Selective Histamine H3 Receptor Inverse Agonist for the Treatment of Narcolepsy: Preclinical Characterization. Sleep, 2019, 42, A50-A50.	1.1	3
24	Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity. Journal of Medicinal Chemistry, 2019, 62, 1203-1217.	6.4	17
25	Methoxsalen as an in vitro phenotyping tool in comparison with 1-aminobenzotriazole. Xenobiotica, 2019, 49, 169-176.	1.1	9
26	Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 457	2.3	4
27	Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects. Clinical Drug Investigation, 2018, 38, 401-415.	2.2	7
28	Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims. Xenobiotica, 2018, 48, 663-675.	1.1	12
29	P2â€080: SUVNâ€502: A PURE 5â€HT₆ ANTAGONIST AMELIORATES MEMORY DEFICIT IN TWO DIFFERENTIALLY CHALLENGED SOCIAL RECOGNITION TASKS. Alzheimer's and Dementia, 2018, 14, P698.	0.8	0
30	A definite measure of occupancy exposures, seeking with non-radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions. Journal of Receptor and Signal Transduction Research, 2018, 38, 359-366.	2.5	1
31	Synthesis, Structureâ€“Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT₄ Receptor Partial Agonists. Journal of Medicinal Chemistry, 2018, 61, 4993-5008.	6.4	27
32	Assessment of sigma-1 receptor occupancy in mice with non-radiolabelled FTC-146 as a tracer. Journal of Receptor and Signal Transduction Research, 2018, 38, 290-298.	2.5	2
33	Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics. Journal of Pharmacological and Toxicological Methods, 2017, 85, 22-28.	0.7	3
34	Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT₆) Receptor Antagonist for Potential Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2017, 60, 1843-1859.	6.4	38
35	Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0%) Tj ETQq1 1 0.784314 rgBT / Sciences, 2017, 101, 80-89.	4.0	15
36	Development and validation of sensitive LCâ€“MS/MS method for the quantification of SUVN-502 and its metabolite and its application for first in human pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 423-430.	2.8	5

#	Article	IF	Citations
37	[P1â€“098]: SUVNâ€502 (5â€HT₆ ANTAGONIST) POTENTIATES THE EFFECTS OF MEMANTINE IN ANIMAL MODELS OF COGNITION. Alzheimer's and Dementia, 2017, 13, P277.	0.8	0
38	[P2â€“033]: SUVNâ€502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P617.	0.8	1
39	Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats. Behavioural Pharmacology, 2016, 27, 225-235.	1.7	1
40	Synthesis of GR 125487, a selective 5-HT₄ receptor antagonist. Synthetic Communications, 2016, 46, 1036-1043.	2.1	1
41	P1â€085: SUVNâ€502, Potent and Pure 5â€HT₆ Receptor Antagonist: Proofâ€ofâ€Concept Study Design in Moderate Alzheimerâ€™s Disease Patients. Alzheimer's and Dementia, 2016, 12, P434.	0.8	2
42	Benzamide derivatives and their constrained analogs as histamine H 3 receptor antagonists. European Journal of Medicinal Chemistry, 2016, 108, 655-662.	5.5	5
43	P1-309: Suvn-d4010: A novel 5-ht4 receptor partial agonist for the treatment of Alzheimer's disease. , 2015, 11, P475-P475.		1
44	P3-296: Safety, tolerability, and pharmacokinetics of a potent and selective 5-ht6 receptor antagonist, SUVN-502, following multiple ascending doses in healthy elderly subjects, and effect of gender and food on single-dose pharmacokinetics. , 2015, 11, P748-P748.		2
45	5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoids. Pharmacological Reports, 2015, 67, 934-942.	3.3	13
46	Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chemico-Biological Interactions, 2015, 230, 9-20.	4.0	11
47	Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. European Journal of Medicinal Chemistry, 2015, 103, 289-301.	5.5	46
48	Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays. Xenobiotica, 2015, 45, 95-106.	1.1	27
49	Inhibitory Effects ofCuminum cyminumon the Mutagenicity of Direct and Indirect Mutagens in Bacterial Reverse Mutation Assay. Journal of Herbs, Spices and Medicinal Plants, 2014, 20, 156-170.	1.1	3
50	Identification of a suitable and selective inhibitor towards aldehyde oxidase catalyzed reactions. Xenobiotica, 2014, 44, 197-204.	1.1	23
51	Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression. Pharmacological Reports, 2014, 66, 394-398.	3.3	5
52	P3-390: EFFECT OF GENDER AND FOOD ON THE SINGLE-DOSE PHARMACOKINETICS OF SUVN-502, A POTENT AND SELECTIVE 5-HT6 RECEPTOR ANTAGONIST. , 2014, 10, P772-P772.		0
53	LCâ€“MS/MS method for the quantification of almotriptan in dialysates: Application to rat brain and blood microdialysis study. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 160-167.	2.8	15
54	Î±4Î²2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain. European Journal of Pharmacology, 2013, 712, 22-29.	3.5	32

#	Article	IF	Citations
55	LCâ€MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. Biomedical Chromatography, 2013, 27, 1431-1437.	1.7	5
56	Aripiprazole in an Animal Model of Chronic Alcohol Consumption and Dopamine D2Receptor Occupancy in Rats. American Journal of Drug and Alcohol Abuse, 2013, 39, 72-79.	2.1	12
57	In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145. Journal of Pharmacy and Pharmacology, 2013, 65, 704-712.	2.4	10
58	Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 155-161.	1.6	14
59	Comparison of manual and automated filaments for evaluation of neuropathic pain behavior in rats. Journal of Pharmacological and Toxicological Methods, 2012, 66, 8-13.	0.7	43
60	Methyllycaconitine: A non-radiolabeled ligand for mapping Î±7 neuronal nicotinic acetylcholine receptors â€" In vivo target localization and biodistribution in rat brain. Journal of Pharmacological and Toxicological Methods, 2012, 66, 22-28.	0.7	8
61	Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT6 Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 9255-9269.	6.4	17
62	Approach to reduce the non-specific binding in microdialysis. Journal of Neuroscience Methods, 2012, 209, 379-387.	2.5	27
63	Pharmacokinetic profiling of efavirenzâ€"emtricitabineâ€"tenofovir fixed dose combination in pregnant and nonâ€pregnant rats. Biopharmaceutics and Drug Disposition, 2012, 33, 265-277.	1.9	14
64	Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task. Brain Research, 2012, 1453, 40-45.	2.2	17
65	Comparison of whole body and head out plethysmography using respiratory stimulant and depressant in conscious rats. Journal of Pharmacological and Toxicological Methods, 2012, 65, 37-43.	0.7	20
66	In vivo receptor occupancy assay of histamine H3 receptor antagonist in rats using non-radiolabeled tracer. Journal of Pharmacological and Toxicological Methods, 2012, 65, 115-121.	0.7	13
67	Rat thalamic Î±4Î²2 neuronal nicotinic acetylcholine receptor occupancy assay using LCâ€"MS/MS. Journal of Pharmacological and Toxicological Methods, 2012, 65, 136-141.	0.7	8
68	Antinociceptive activity of Î±4Î²2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. European Journal of Pharmacology, 2011, 668, 155-162.	3.5	23
69	Quantification of methyllycaconitine, selective Î±₇ nicotinic receptor antagonist, in rodent plasma and brain tissue by liquid chromatography tandem mass spectrometry â€" application to neuropharmacokinetics of methyllycaconitine in rats. Biomedical Chromatography, 2011, 25, 1273-1282.	1.7	5
70	Rigidized 1-aryl sulfonyl tryptamines: Synthesis and pharmacological evaluation as 5-HT6 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4577-4580.	2.2	19
71	5-HT₄ Receptor Agonists for the Treatment of Alzheimerâ€™s Dsease. Neuroscience and Medicine, 2011, 02, 87-92.	0.2	11
72	Quantification of acetylcholine, an essential neurotransmitter, in brain microdialysis samples by liquid chromatography mass spectrometry. Biomedical Chromatography, 2010, 24, 39-48.	1.7	43

#	Article	IF	Citations
73	Simultaneous quantification of a nonâ€nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. Biomedical Chromatography, 2009, 23, 371-381.	1.7	38
74	Quantification of the Cephalosporin Antibiotic Cefditoren in Human Plasma by High-performance Liquid Chromatography. Arzneimittelforschung, 2006, 56, 309-313.	0.4	2
75	Quantification of Faropenem in Human Plasma by High-performance Liquid Chromatography. Arzneimittelforschung, 2005, 55, 762-766.	0.4	3